Retinoblastoma in older patients: A retrospective comparative analysis of 100 consecutive patients based on age

Babak Masoomian, Lauren A. Dalvin, Michael D. Yu, Christina Stathopoulos, Carol L. Shields

Abstract

Purpose: To describe comparative clinical features, treatment, and outcomes of retinoblastoma in patients initially diagnosed at age 4 or older.

Methods: Retrospective case series.

Results: There were 101 eyes in 100 consecutive patients age ≥4 years diagnosed with retinoblastoma. Mean patient age at diagnosis was 6.6 years (median 5.3, range 4.0–41.0 years). Tumors were predominantly classified (International Classification of Retinoblastoma) as group D (31%) or E (65%). Patients were divided by age into 3 groups: young (4–6 years [65%]), middle (>6–8 years [23%]), and older (>8 years [12%]). Comparing by age group (young vs. middle vs. older), mean tumor basal diameter (19.9 vs. 17.3 vs. 17.0 mm, \( p = 0.05 \)) and mean tumor thickness (11.0 vs. 9.4 vs. 7.0 mm, \( p < 0.01 \)) were greatest in the youngest group. Distance to the optic nerve (1.5 vs. 1.7 vs. 5.0 mm, \( p = 0.01 \)) and foveola (1.9 vs. 1.8 vs. 6.0 mm, \( p < 0.01 \)) were greatest in the oldest age group. Objective findings of leukocoria and strabismus were more common in younger patients, while older patients complained of subjective findings, like decreased vision (19% vs. 30% vs. 60%, \( p < 0.01 \)) and floaters (3% vs. 4% vs. 17%, \( p = 0.05 \)). Primary treatment included enucleation (76%) and other modalities (24%). Globe salvage rate was 13%, with no significant difference by age. Comparison of globe salvage by revealed significant improvement between 1974–2008 (6%) and 2009–2017 (38%, \( p < 0.01 \)).

Conclusion: Retinoblastoma in older patients (>8 years) tends to be smaller and more peripherally located, with more subjective presenting symptoms.

Keywords: Eye, Cancer, Retinoblastoma, Late-onset retinoblastoma, Age older, Teenager, Adult, Globe salvage

Introduction

Retinoblastoma (RB) is generally detected before 3 years of age.\(^1\) For patients with bilateral RB, mean age at detection is 12 months, and in those with unilateral RB, mean age at detection is 24 months.\(^2\) In an analysis of 528 patients with RB managed at a tertiary referral center from 1989 to 2001, mean patient age was 22 months (median 15 months) at the time of referral.\(^3\) Information from the Surveillance Epidemiology and End Results (SEER) database from 1975 to 2010 with a cohort of 1452 patient revealed mean age at detection of 1 year.\(^4\) Detection of RB at ages older than 4 years is considered unusual.\(^1\)
In 1919, for the first time, Maghy described bilateral RB in an adult, a 20-year-old woman. Since then, RB in older patients has been described in case reports and small case series. The pathophysiology for late-onset development of RB is speculative. Some postulate that it represents malignant transformation of a benign retina (retinocytoma); and others question whether new mutations can exist [6]. Kaliki et al. speculated that RB1 mutation in persistent embryonic retinal cells could unlock the potential for proliferation and ultimately lead to late-onset RB. In 1991, Shields et al. reviewed 26 cases of RB diagnosed in patients older than 5 years of age and noted several atypical findings of this malignancy in older patients, including hypopyon, hypHEMA, uveitis, endophthalmitis, and hemorrhage. In their study, 6 of 26 (23%) patients presented with vitreous hemorrhage or inflammation (endophthalmitis-like) that prevented fundoscopic identification of the tumor and delayed diagnosis of RB. Advanced disease was common, necessitating enucleation in 24 of 26 (92%) cases. These findings were corroborated in 2015 by Kaliki et al. in a series of 8 adults with RB presenting after age 20 years. Atypical signs were likewise common, and advanced disease required enucleation in 5 of 8 (62%) cases. As a result of atypical findings and delayed diagnosis, older patients with RB have typically been managed with enucleation.

In recent years, the management of RB has evolved dramatically with novel use of intravenous, intra-arterial, and intra-vitreous chemotherapy. Thus, the clinical course of older patients with RB warrants reexamination. In this report, we explore the presenting symptoms, clinical features, and outcomes of 100 consecutive patients with late-onset RB, diagnosed at age 4 years (48 months) or older.

Methods

All patients with RB managed on the Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA between January 1, 1974 and March 31, 2017 were retrospectively reviewed. Informed consent was obtained from the patient’s parent or legal guardian. Institutional Review Board approval was obtained from Wills Eye Hospital, and this study adhered to the tenets of the Declaration of Helsinki and HIPAA.

All patients with newly diagnosed active RB who were ≥4 years (48 months) old at the time of initial diagnosis were included. Patients with an initial diagnosis of retinoma or retinocytoma (also known as arrested retinoblastoma or spontaneously regressed RB) were excluded. Diagnosis of RB was based on ophthalmic examination under general anesthesia with indirect ophthalmoscopy, Retcam fundus photography (Clarity, Pleasanton, CA), fluorescein angiography, and B-scan ultrasonography. Involved eyes were classified according to International Classification of Retinoblastoma (ICRB) group.

Patient data collected included age at diagnosis, sex, race, laterality, genetic pattern when available (somatic/germine), and best corrected visual acuity. Baseline tumor features included laterality, number of tumors, tumor size (largest basal diameter and thickness, in mm), distance of the main tumor from the foveola and optic disc (in mm), anterior chamber, vitreous and subretinal seeding, intraocular pressure, iris neovascularization, vitreous hemorrhage, and retinal detachment. Tumor treatment included enucleation, intravenous chemotherapy (IVC), intra-arterial chemotherapy (IAC), intravitreal chemotherapy (IVtC), cryo therapy, photoagulation, plaque radiotherapy, and external beam radiotherapy (EBRT).

Histopathology features of enucleated eyes included anterior chamber involvement, choroidal invasion (focal if <3 mm in diameter and massive if ≥3 mm in diameter), optic nerve invasion (pupil, retrolaminar, or tumor at surgical margin), and extraocular involvement. Mean follow-up and mean event-free follow-up were recorded in years. Primary outcomes were globe salvage and status of patient at last follow-up (alive and well, alive with metastasis, expired due to metastasis, or expired due to unrelated causes).

Data were recorded and tabulated in Microsoft Excel 2011 (Microsoft, Seattle, WA). Analyses for measures of central tendency (mean and median), range, and frequency were performed using built-in functions of the software. Subgroup analysis by age (4–6 years, >6–8 years, and >8 years) was performed to determine differences between groups. JMP statistical analysis software (JMP Pro 13.0.0, Cary, NC) was used to compare categorical and continuous data between groups using Fisher’s exact test and ANOVA.

Results

There were 101 eyes in 100 consecutive patients with RB age ≥4 years at initial diagnosis. Patient demographics are listed in Table 1. Mean age at initial diagnosis was 6.6 years (median 5.3, range 4.0–41.0). A comparison of 3 age groups (young [4–6 years] vs. middle [>6–8 years] vs. older [>8 years]) revealed significant differences in female sex (58% vs. 30% vs. 33%, p = 0.03). Genetic testing was conducted in 28 (28%) cases, revealing somatic mutation in 22 (22%) and germline mutation in 6 (6%). Presenting symptoms of leukocoria (62% vs. 39% vs. 25%, p = 0.01) and strabismus (12% vs. 4% vs. 0%, p = 0.10) were more common in the younger age groups, while older patients complained more often of decreased vision (19% vs. 30% vs. 60%, p < 0.01) and floaters (3% vs. 4% vs. 17%, p = 0.05).

Tumor classification (ICRB) varied between age groups, with a higher prevalence of group E (58% vs. 83% vs. 67%, p = 0.03) in the middle and older groups. There was no significant difference in visual acuity ≥20/200 (30%) and <20/200 (70%) by age (p = 0.21).

A comparison of tumor features by age (Table 1) revealed that older patients had smaller tumors by mean largest basal diameter (19.9 vs 17.3 vs 17.0 mm, p = 0.05) and mean thickness (11.0 vs. 9.4 vs. 7.0 mm, p < 0.01). In older patients, tumors were more peripheral, with greater mean distance from the optic nerve (1.5 vs. 1.7 vs. 5.0 mm, p = 0.01) and foveola (1.9 vs. 1.8 vs. 6.0 mm, p < 0.01). Presence of anterior segment seeds (11% vs. 43% vs. 8%, p < 0.01), retinal detachment (62% vs. 48% vs. 33%, p = 0.05), and subretinal seeds (83% vs. 65% vs. 58%, p = 0.02) varied significantly by age group. There was no significant difference by age in the prevalence of neovascular glaucoma (p = 0.34), vitreous seeds (p = 0.14), and vitreous hemorrhage (p = 0.67).

Treatment features and outcomes are listed in Table 2. Primary treatment included enucleation (76%), IVC (5%), IAC (8%), plaque radiotherapy (5%), and EBRT (6%). Use of EBRT was significantly higher in the older age group (5% vs. 0% vs.
Secondary enucleation was required in an additional 11 of 24 eyes ($p = 0.70$) following treatment failure with other methods. Globe salvage was achieved in 13% of cases with no significant difference between age groups ($p = 0.07$). By treatment modality, globe salvage was achieved in 4/6 eyes (66%) with EBRT, 2/5 (40%) with plaque, and 5/11 (45%) with plaque and EBRT.

### Table 1. Comparative analysis of 100 consecutive patients with active retinoblastoma in 101 eyes at an older age (≥4-years-old). Patient demographics and clinical features.

| Patient demographics | Patient age at initial presentation |
|----------------------|------------------------------------|
|                      | 4–6 years old | ≥6–8 years old | >8 years old | p-value | Combined |
| (n = 65) [n (%)]     | (n = 23) [n (%)] | (n = 12) [n (%)] | (n = 100) [n (%)] |
| Age at presentation (years) [mean (median, range)] | 4.7 (4.6–6) | 6.9 (6.6–2–8) | 16.4 (11.7, 8.3–40.5) | <0.01 | 6.6 |
| Sex                  |                      |                      |                      |       |
| Male                 | 27 (42)              | 16 (70)              | 8 (67)               |       |
| Female               | 38 (58)              | 7 (30)               | 4 (33)               | 0.03  | 49 (49) |
| Presenting symptom   |                      |                      |                      |       |
| Decreased vision     | 12 (19)              | 7 (30)               | 7 (60)               | <0.01 | 26 (26) |
| Leukocoria           | 40 (62)              | 9 (39)               | 3 (25)               | <0.01 | 52 (52) |
| Strabismus           | 8 (12)               | 1 (4)                | 0 (0)                | 0.10  | 9 (9)   |
| Hypopyon             | 0 (0)                | 1 (4)                | 0 (0)                | 0.07  | 1 (1)   |
| Pain                 | 2 (3)                | 1 (4)                | 2 (17)               | 0.05  | 5 (5)   |
| Floaters             | 1 (2)                | 1 (4)                | 0 (0)                | 0.33  | 2 (2)   |
| None                 | 1 (2)                | 1 (4)                | 0 (0)                | 0.33  | 2 (2)   |
| Genetic testing      |                      |                      |                      |       |
| Somatic mutation     | 16 (25)              | 4 (18)               | 2 (17)               | 0.35  | 22 (22) |
| Germiline mutation   | 3 (4)                | 1 (4)                | 2 (17)               | 0.10  | 6 (6)   |
| Not available        | 46 (71)              | 18 (78)              | 8 (67)               | 0.41  | 72 (72) |
| Affected eye(s)      |                      |                      |                      |       |
| Unilateral Rb        | 63 (97)              | 22 (96)              | 11 (92)              | 0.68  | 96 (96) |
| Bilateral Rb         | 1 (2)                | 0 (0)                | 0 (0)                | 0.46  | 1 (1)   |
| Contralateral retinoma | 1 (2)              | 1 (4)                | 1 (9)                | 0.18  | 3 (3)   |
| Clinical Features    |                      |                      |                      |       |
|                      | (n = 66) [n (%)] | (n = 23) [n (%)] | (n = 12) [n (%)] | (n = 100) [n (%)] |
| ICRB classification  |                      |                      |                      |       |
| Group B              | 1 (1)                | 1 (4)                | 0 (0)                | 0.33  | 2 (2)   |
| Group C              | 2 (3)                | 1 (4)                | 0 (0)                | 0.47  | 3 (3)   |
| Group D              | 25 (38)              | 2 (9)                | 4 (33)               | <0.01 | 31 (30) |
| Group E              | 38 (58)              | 19 (83)              | 8 (67)               | 0.03  | 65 (65) |
| Tumors per eye       | 1 (1; 1–2)           | 1 (1; 1–2)           | 1 (1; 1–1)           | 0.61  | 1 (1; 1–2) |
| [mean (median, range)] |                      |                      |                      |       |
| Largest tumor diameter (mm) | 19.9 | 17.3 | 17.0 | 0.05 | 19.0 |
| [mean (median, range)] | (21.0; 4.5–25.0) | (18.5; 5.0–25.0) | (16.0; 11.0–24.0) | (20.0; 4.5–25.0) |
| Tumor thickness (mm) | 9.4 | 7.0 | 0.01 | 10.0 |
| [mean (median, range)] | (10.0; 2.6–18.0) | (9.0; 2.0–17.0) | (6.15; 4.0–13.0) | (10.0; 2.0–18.0) |
| Distance to optic nerve (mm) | 1.5 | 1.7 | 5.0 | 0.01 | 2.0 |
| [mean (median, range)] | (0.0; 0.0–11.0) | (0.0; 0.0–10.0) | (3.5; 0.0–10.0) | (0.0; 0.0–11.0) |
| Distance to foveola (mm) | 1.9 | 1.8 | 6.0 | <0.01 | 2.0 |
| [mean (median, range)] | (0.0; 0.0–11.0) | (0.0; 0.0–10.0) | (6.0; 0.0–12.0) | (0.0; 0.0–12.0) |
| Vitreous seeds        |                      |                      |                      |       |
| None                 | 6 (9)                | 4 (17)               | 0 (0)                | 0.10  | 10 (10) |
| Present              | 57 (86)              | 19 (83)              | 12 (100)             | 0.14  | 88 (88) |
| No view              | 3 (5)                | 0 (0)                | 0 (0)                | 0.19  | 3 (2)   |
| Subretinal seeds     |                      |                      |                      |       |
| None                 | 11 (17)              | 8 (35)               | 5 (42)               | 0.02  | 24 (24) |
| 1 quadrant           | 4 (6)                | 0 (0)                | 0 (0)                | 0.14  | 4 (3)   |
| 2 quadrants          | 8 (12)               | 0 (0)                | 1 (8)                | 0.08  | 9 (9)   |
| 3 quadrants          | 8 (12)               | 1 (4)                | 1 (8)                | 0.27  | 10 (10) |
| 4 quadrants          | 12 (18)              | 6 (26)               | 2 (17)               | 0.40  | 20 (20) |
| No view              | 23 (35)              | 8 (35)               | 3 (25)               | 0.48  | 34 (34) |
| Retinal detachment   |                      |                      |                      |       |
| None                 | 25 (38)              | 12 (52)              | 8 (67)               | 0.05  | 45 (45) |
| 1 quadrant           | 5 (7.5)              | 2 (9)                | 1 (8)                | 0.86  | 8 (8)   |
| 2 quadrants          | 9 (14)               | 3 (13)               | 0 (0)                | 0.17  | 12 (11) |
| 3 quadrants          | 5 (7.5)              | 2 (9)                | 1 (8)                | 0.86  | 8 (8)   |
| 4 quadrants          | 22 (33)              | 4 (17)               | 2 (17)               | 0.08  | 28 (28) |
| No view              | 12 (18)              | 5 (22)               | 2 (17)               | 0.67  | 19 (19) |
| Vitreous hemorrhage  |                      |                      |                      |       |
| Anterior segment findings |            |                      |                      |       |
| Anterior chamber seeds | 7 (11)              | 10 (43)              | 1 (8)                | <0.01 | 18 (18) |
| Iris neovascularization | 24 (36)             | 9 (39)               | 3 (25)               | 0.39  | 36 (36) |
| Neovascular glaucoma | 15 (23)              | 7 (30)               | 2 (17)               | 0.34  | 24 (24) |
| Visual acuity        | (n = 62)             | (n = 23)             | (n = 12)             | (n = 97) |
| ≥20/200              | 16 (26)              | 8 (35)               | 5 (42)               | 0.21  | 29 (30) |
| <20/200              | 46 (74)              | 15 (65)              | 7 (58)               | 0.68  | 70 (70) |
optic nerve involvement (p = 0.46), postlaminar invasion (p = 0.59), or extraocular extension (p = 0.64). By histopathologic examination, tumor was present at the optic nerve resection margin in 1 (1%) case.

Patients were also divided into 3 groups by date of initial examination: 1974–1994, 1995–2008, and 2009–2017 (Table 3), with each era corresponding to the advent of a new treatment modality (pre-chemotherapy era, IVC era, and IAC era). Comparison of globe salvage rate by date of initial examination showed significant improvement in the most recent group (11% vs. 2% vs. 38%, p < 0.01) (Fig. 1).

Discussion

The differential diagnosis of an amelanotic tumor arising in the fundus of an older child (≥4 years old) or adult includes a variety of inflammatory, infectious, and neoplastic conditions such as retinal and choroidal inflammatory/infectious disease, choroidal nevus, melanoma, lymphoma, osteoma, hemangiomata, retinociliary leukemia, retinal astrocytic tumors, benign retinoma/retinocytoma, and RB. The overall mean age-adjusted annual incidence of RB is 11.8 per million for children aged 0–4 years, and 0.6 per million in children aged 5 years and older. Approximately 80% of RB cases are diagnosed by age 4, and, according to a study in the Netherlands, screening for hereditary RB is recommended until 4 years of age. In this study, we specifically examined clinical features and outcomes for older patients with RB, diagnosed at age 4 or later.

The diagnosis of RB is readily made when found in a young child with characteristic findings of leukocoria and a white retinal mass. However, older children often present with atypical symptoms or smaller, more peripheral lesions that can simulate infectious or inflammatory etiology and pose a diagnostic dilemma. The most common presenting features for RB in young patients include leukocoria (56%), strabismus

### Table 2. Comparative analysis of 100 consecutive patients with active retinoblastoma in 101 eyes at an older age (≥4-years-old). Treatment features, treatment outcomes, and enucleation histopathologic features.

| Treatment type | 4–6 years old | >6–8 years old | >8 years old | p-value | Combined |
|----------------|---------------|---------------|-------------|---------|----------|
| Primary enucleation | (n = 66) [n (%)] | (n = 23) [n (%)] | (n = 12) [n (%)] | (n = 101) [n (%)] |
| Optic nerve involvement | 22 (39) | 5 (25) | 2 (25) | 0.46 | 29 (34) |
| Posterior | 14 (25) | 2 (10) | 0 (0) | 0.13 | 16 (19) |
| Tumor cells at surgical sect. | 8 (14) | 2 (10) | 2 (25) | 0.59 | 12 (14) |
| Choroidal involvement | 17 (30) | 6 (30) | 2 (25) | 0.96 | 25 (29) |
| Focal (<3mm) | 5 (9) | 4 (20) | 1 (13) | 0.41 | 10 (12) |
| Massive (≥3mm) | 10 (18) | 2 (10) | 1 (13) | 0.70 | 13 (15) |
| Not described | 2 (3) | 0 (0) | 0 (0) | 0.60 | 2 (2) |
| Anterior chamber involvement | 1 (2) | 1 (5) | 0 (0) | 0.64 | 2 (2) |

* Both patients with systemic metastasis expired.
* Histopathologic features were not available for 3 enucleations in the 4–6 years old group performed elsewhere.
Table 3. Comparative analysis of 100 consecutive patients with active retinoblastoma in 101 eyes at an older age (≥4-years-old). Treatment outcomes by date first seen.

| Features                        | Year of initial visit | p-value | Combined   |
|---------------------------------|-----------------------|---------|------------|
|                                 | 1974–1994 (n = 37) [%] |         | (n = 101) [%] |
| Follow-up duration (years) [mean (median, range)] | 7 (6; 0–34)           |         | 5 (3; 0–34)* |
| Event-free follow-up (years) [mean (median, range)] | 7 (6; 0–34)           |         | 5 (3; 0–34)* |
| Globe salvage                   | 4 (11)                |         | 13 (13)    |
| Systemic metastasis**           | 1 (3)                 |         | 2 (2)      |
| Secondary cancers               | 0 (0)                 |         | 0 (0)      |
|                                 | 1995–2008 (n = 43) [%] |         | (n = 101) [%] |
| Follow-up duration (years) [mean (median, range)] | 5 (4; 0–17)           | <0.01   | 5 (3; 0–34)* |
| Event-free follow-up (years) [mean (median, range)] | 5 (4; 0–17)           | <0.01   | 5 (3; 0–34)* |
| Globe salvage                   | 1 (2)                 |         | 8 (38)     |
| Systemic metastasis**           | 0 (0)                 |         | 1 (8)      |
| Secondary cancers               | 0 (0)                 |         | 0 (0)      |
|                                 | 2009–2017 (n = 21) [%] |         | (n = 101) [%] |
| Follow-up duration (years) [mean (median, range)] | 2 (1; 0–4)            |         | 5 (3; 0–34)* |
| Event-free follow-up (years) [mean (median, range)] | 1 (1; 0–4)            | <0.01   | 5 (3; 0–34)* |
| Globe salvage                   | 8 (38)                |         | 13 (13)    |
| Systemic metastasis**           | 1 (8)                 |         | 2 (2)      |
| Secondary cancers               | 0 (0)                 |         | 0 (0)      |

* Three patients were enucleated elsewhere and were lost to follow-up.
** Both patients with systemic metastasis expired.

Fig. 1. (A) A 5-year-old boy with group D retinoblastoma (RB) in 2003 was treated with primary enucleation. (B) A 6-year-old boy with group D RB in 2006 was treated with primary enucleation. (C) A 6-year-old girl with group E RB in 2013, was treated with intra-arterial chemotherapy, and showed good tumor regression after 12 months (D). (E) A 6-year-old girl with group D RB in 2016 was treated with intra-arterial chemotherapy and showed good tumor regression after 17 months (F).
(24%), and decreased vision (5%). In a series of older RB patients by Shields et al, subjective symptoms such as decreased vision (35%) were found to be more common than objective findings of leukocoria (35%) and strabismus (15%).

In our study, leukocoria (51%), decreased vision (26%), and strabismus (9%) were the most common presenting findings, although we observed a decreased prevalence of leukocoria ($p < 0.01$) and strabismus ($p = 0.1$) with age, consistent with prior reports. Moreover, atypical signs of RB, including hypopyon, anterior chamber cells simulating uveitis, and/or vitreous hemorrhage, are known to occur more frequently in cases of late-onset RB and often lead to misdiagnosis with delayed treatment (Fig. 2). In this study, 14 (14%) patients were initially misdiagnosed, with referring diagnoses of Coats disease ($n = 5, 5%$), uveitis/endophthalmitis ($n = 4, 4%$), vitreous hemorrhage with retinal detachment ($n = 3, 3%$), or toxocariasis ($n = 2, 2%$). Two patients had previously undergone pars plana vitrectomy with biopsy for diagnostic uncertainty elsewhere, and both required urgent primary enucleation by our team, neither developing metastasis. Consideration of RB with atypical features in older patients might prevent unnecessary procedures that often culminate in enucleation.

Analysis of clinical features of RB in this study showed no significant differences by age (age 4–6 vs. >6–8 vs. > 8 years) for vitreous seeds, subretinal seeds, retinal detachment, vitreous hemorrhage, or optic nerve involvement. However, there were significant differences in features by age in that the oldest patients (>8 years) had smaller tumor thickness (11 vs. 9.4 vs. 7.0 mm, $p < 0.01$) and basal diameter (19.9

Fig. 2. Atypical features of retinoblastoma (RB) in older patients. (A) A 22-year-old woman with subluxed lens from a (B) mushroom-shaped, minimally calcified ciliochoroidal mass confirmed on cytopathology as RB. (C) A 6-year-old boy, diagnosed elsewhere as Coats disease one year prior, presented with advanced RB with buphthalmos, scleral ectasia, and anterior chamber seeding. (D) An 8-year-old girl with blurry vision was found to have vitreous hemorrhage from an amelanotic retinal vascular mass with (F) vitreous seeding, suggestive of RB. The patient was successfully treated with intra-arterial and intravitreal chemotherapy.
vs. 17.3 vs. 17.0 mm, \( p = 0.05 \), with more peripherally located tumors farther from the optic disc (1.5 vs. 1.8 vs. 5.0 mm, \( p = 0.01 \)) and foveola (1.9 vs. 1.8 vs. 6.0 mm, \( p < 0.01 \)). Smaller, more peripheral tumors could be less symptomatic and less easily visualized on funduscopy examination, resulting in delay in diagnosis and treatment in these patients. This is consistent with prior series of adult RB, which reported a mean duration of symptoms before diagnosis of 12–15 months.\(^6\)\(^{13}\) Insidious symptoms in older-onset and adult RB patients can result in loss of considerable time before seeking ophthalmic consultation, which might explain the preponderance for group D (30%) and E (65%) eyes in this study.

Globe-preserving treatment in advanced RB (groups D and E) is challenging and currently involves mostly IAC or IVtC.\(^1\) Management of late-onset RB in this series was determined by the stage of disease and standard of care at the time of presentation. Most cases presented with advanced disease requiring enucleation. Primary enucleation was performed for 77 (76%) eyes. Of the remaining 24 (24%) eyes, which were treated with chemotherapy (IVC or IAC) and/or radiation (EBRT or plaque radiotherapy), treatment failure occurred in 11 eyes, necessitating secondary enucleation. Although there was no difference for globe salvage between age groups, comparison by date of first visit (Table 3) showed a marked increase of globe salvage from 6% in the pre-chemotherapy and intravenous chemotherapy years (1974–2008) to 38% in the IAC years (2009–2017), reflecting the important roles that IAC and IVtC have in improving globe salvage rates.\(^{16}\)\(^{18}\) A study of 249 eyes by Shields et al. showed that when IVC was used alone as first-line therapy for RB, globe salvage rate was 100% for group A, 93% for group B, 90% for group C, and 47% for group D.\(^{16}\) Enucleation, rather than IVC, was typically performed for group E.\(^{16}\) A more recent study by Shields et al. demonstrated that IAC provided significantly improved globe salvage over IVC in group D eyes (91% vs. 47%, \( p = 0.004 \)), with globe salvage of 36% in group E eyes by IAC.\(^{17}\) Furthermore, the recent introduction of IVtC has further improved globe salvage for group E eyes from 25% before IVtC to 83% after introduction of IVtC.\(^{18}\)\(^{19}\)

In spite of advanced local disease in 95% of cases in our study, metastatic RB was found in only 2 cases (2%). Both patients presented to us with systemic metastasis secondary to delayed diagnosis. Despite receiving targeted treatment, both patients expired from brain metastasis. New modalities of treatment and the use of IVC (after 1994) have likely contributed to reduction in risk of metastatic disease. Improved detection of RB will likely lead to further reduction in risk of metastasis.

Strengths of our study included mean follow-up of 60 months, access to clinical photographs for all patients, and a large sample size, which allowed us to detect previously unreported trends in RB tumor size and location in older patients. Admittedly, this study contains the weaknesses inherent to any retrospective, non-randomized study, including lack of standardized treatment plans across all patients. However, this study accurately reflects individualized treatments that are tailored to each patient, with the highest standard of care available at the time of first visit being provided. The standard of care during the study period varied widely, as this study spanned three major eras in RB treatment: pre-chemotherapy, IVC, and IAC.

In summary, the diagnosis of RB should be considered for amelanotic fundus tumors in patients of any age group, even in adults. Although globe salvage rates for RB in older patients have historically been poor, early recognition of this entity and trials of newer treatment modalities, particularly IAC and IVtC, can contribute to improved outcomes.

**Declaration of Competing Interest**

The authors declared that there is no conflict of interest.

**Acknowledgement**

Support provided in part by the Eye Tumor Research Foundation, Philadelphia, PA (CLS), an unrestricted grant from Research to Prevent Blindness, Inc (LAD), and the Heed Ophthalmic Foundation (LAD). The funders had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review or approval of the manuscript. Carol L. Shields, M.D. has had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**References**

1. Shields JA, Shields CL. Intraocular tumors. An atlas and textbook. 3rd ed. Philadelphia, PA: Lippincott Wolters Kluwer; 2016. p. 311–87.
2. Andreoli MT, Chau FY, Shapiro MJ, Leiderman YI. Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry. Can J Ophthalmol 2017;52(6):592–8.
3. Epstein JA, Shields CL, Shields JA. Trends in the management of retinoblastoma: evaluation of 1,196 consecutive eyes during 1974 to 2001. J Pediatr Ophthalmol Strabismus 2003;40(4):196–203.
4. Maghy C. A case of bilateral glioma of the retina in a girl twenty year of age which the second eye was excised after an interval of nearly eighteen years. Br J Ophthalmol 1919;3:337–40.
5. Shields CL, Shields JA, Shah P. Retinoblastoma in older children. Ophthalmology 1991;98:395–9.
6. Kaliki S, Shields CL, Gupta A, et al. Newly diagnosed active retinoblastoma in adults. Retina 2015;35(12):2483–8.
7. Finlay JR, Byron H. Retinoblastoma in the adult: review of literature and report of case associated with a benign melanoma. Acta XIX Concil Ophthalmol (New Delhi) 1962;2:1168–78.
8. Biswas J, Mani B, Shanmugam MP, et al. Retinoblastoma in adults. Report of three cases and review of the literature. Surv Ophthalmol 2000;44(5):409–14.
9. De Aguirre Neto JC, Antoneli CB, Ribeiro KB, et al. Retinoblastoma in children older than 5 years of age. Pediatr Blood Cancer 2007;48(3):292–5.
10. Nork TM, Millechia LL, de Venecia GB, et al. Immunocytochemical features of retinoblastoma in an adult. Arch Ophthalmol 1996;114:1402–6.
11. Wells JR, Aaberg Jr TM, Shields CL, Comer GM, Grossniklaus HE. Retinoblastoma in A 48-year-old woman. Retinal Cases Brief Rep 2011;5(1):22–5. https://doi.org/10.1097/ICB.0b013e3181e17fa6.
12. Zhang Z, Shi JT, Wang NL, Ma JM. Retinoblastoma in a young adult mimicking coats’ disease. Int J Ophthalmol 2012;5(5):625–9.
13. Sengupta S, Pan U, Khetan V. Adult onset retinoblastoma. Indian J Ophthalmol 2016;64(7):485–91.
14. Karcgiolu ZA, Abboud EB, Al-Mesfer SA, Al-Rashed W, Pilapil DH. Retinoblastoma in older children. JAAPOS 2002;6(1):26–32.
15. Singh AD, Santos CM, Shields CL, Shields JA, Eagle Jr RC. Observations on 17 patients with retinocytoma. Arch Ophthalmol 2000;118:199–205.
16. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113(12):2276–80.
17. Shields CL, Jorge R, Say EA, et al. Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma. Asia Pac J Ophthalmol 2016; 5(2): 97–103.

18. Shields CL, Alset AE, Say EA, Caywood E, Jabbour P. Retinoblastoma control with primary intra-arterial chemotherapy: outcomes before and during the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus 2016; 53(5): 275–84.

19. Ghassemi F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol 2014; 132(8): 936–41.

20. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009; 93(1): 21–3.

21. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990; 108(1): 128–32.

22. Moll AC, Imhof SM, Meeteren AY, Boers M. At what age could screening for familial retinoblastoma be stopped? A register-based study 1945–98. Br J Ophthalmol 2000 Oct; 84(10): 1170–2.

23. Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW. Presenting signs of retinoblastoma. J Pediatr 1998; 132: 505–8.

24. Stafford WR, Yanoff M, Parnell BL. Retinoblastomas initially misdiagnosed as primary ocular inflammations. Arch Ophthalmol 1969; 82(6): 771–3.